Could AbbVie's New Collaboration Be a Blockbuster?

Earlier this month, AbbVie (NYSE: ABBV) announced a deal with biotechnology company Regenxbio (NASDAQ: RGNX) to treat eye disorders using gene therapy. Specifically, the two companies are collaborating to develop and commercialize a gene therapy candidate, RGX-314, which is currently in phase 2 clinical trials.

Let's take a deeper look at this agreement, and the potential revenue it could generate for AbbVie.

Image source: Getty Images.

Continue reading

Source Fool.com